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in 2000 and later, 6 used reduced intensity conditioning. Two
patients had persistent disease, four died prior to 30 days post
transplant and it was assumed that all others achieved remission.
Four allogeneic and one autologous recipient relapsed, all within 3
years post transplant. For allogeneic transplants, the 5-year overall
survival probability was 48% with lower and upper bounds of 31%
and 65%, which is comparable to the ﬁnding of 47% in a recent
EBMT study [1]. Transplant related mortality at 100 days was
19.6%. There were 16 deaths in the ﬁrst year post transplant
among allogeneic and syngeneic recipients, from infection (7),
GVHD (4), organ failure (3) and persistent disease (2). Both au-
tologous recipients died, from septicaemia at 6 months and relapse
at 2.3 years post transplant. The ABMTRR is an important na-
tional data resource which enables accurate and timely analysis of
transplant activity and outcome, particularly for rare indications
that have relatively small numbers.
1. Guardiola P, et al. Allogeneic stem cell transplantation for
agnogenic myeloid metaplasia: a European Group for Blood and
Marrow Transplantation, Societe Francaise de Greffe de Moelle,
Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred
Hutchinson Cancer Research Center collaborative study. Blood.
1999;93:2831-2838.
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LOW INCIDENCE OF ACUTE GRAFT VERSUS HOST DISEASE AND RE-
DUCED EARLY MORTALITY IN CP-CML PATIENTS TRANSPLANTED US-
ING CSA, MTX AND MP AS IMMUNOPROPHYLAXIS
Funke, V.M., Setubal, D.C., Ruiz, J., Lima, D.H., Bonﬁm, C.M.,
Bitencourt, M.A., Zanis-Neto, J., de Medeiros, C.R., Pasquini, R.
Hospital de Clı´nicas-Federal University of Parana, Curitiba, Parana,
Brazil.
Signiﬁcant early transplant related mortality is one of the factors
that have impacted the reduction of transplants for CML, espe-
cially in the imatinib era. However, curative potential of bone
marrow transplantation has to be taken into consideration, espe-
cially for young high risk patients. Patients and Methods: We
report here long-term results from a single center experience of
166 patients submitted to bone marrow transplantation for chronic
phase CML from 1990 to 2004. All patients received marrow from
sibling HLA identical donors, and used BU  CY as the condi-
tioning regimen and cyclosporine, methotrexate and a short course
of MP (1 mg/kg/day from day 14 to day 28, then tapered 20%
per week) as immunoprophylaxis. Male: 92; female 74. Median age
was 33 years (range 6-51). Median duration of disease was 20
months (4-87). Univariate and multivariate analysis of risk factors
for survival were performed. Age, disease duration before trans-
plant, female donor  male patient, time of engraftment, acute
GVHD and chronic GVHD were analyzed risk factors. Results:
Mortality before day 100 was 8%. Grade III-IV acute GVHD
occurred in only 7% of the patients. From 153 patients who survived
more than 100 days, 63 (38%) developed extensive chronic graft-
versus-host disease. Median survival was 2498 days (58-5391). Overall
survival and estimated disease free survival in 14 years was 71%. Only
the presence of grade III-IV of acute and extensive chronic graft-
versus-host disease were identiﬁed as independent risk factors for
survival. Causes of death included: c-GVHD (13%), infections (9%)
and progressive disease (7%). Conclusions: The addition of MP to
the immunoprophylaxis regimen has effectively reduced the incidence
of grade III-IV acute GVHD and early transplant related mortality.
No inﬂuence was seen on chronic GVHD incidence, overall survival
or disease free survival.
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PREDICTIVE FACTORS AND IMPACT OF FULL DONOR T-CELL CHIMER-
ISM AFTER REDUCED INTENSITY CONDITIONING (RIC) ALLOGENEIC
STEM CELL TRANSPLANTATION (ALLO-SCT)
Mohty, M.1, Avinens, O.2, Faucher, C.1, Furst, S.1, Viens, P.1,
Gastaut, J.-A.1, Eliaou, J.-F.2, Blaise, D.1 1Institut Paoli-Calmettes,
Marseille, France; 2CHU de Montpellier, Montpellier, France.
The kinetics of lineage-speciﬁc chimerism proved to be an im-
portant issue after RIC allo-SCT. Here, we investigated the impact
of different factors on the establishment of full donor CD3T cell
chimerism (TCC) in a series of 102 patients receiving RIC allo-
SCT from an HLA-identical sibling. 65 patients received an ATG-
based RIC regimen (ﬂudarabine, busulfan and ATG), 14 patients
received a low dose TBI-based RIC (2 Gy), while the remaining 23
patients received an association of ﬂudarabine, busulfan and total
lymphoid irradiation (TLI; 1.7 Gy). At day 30, 30% (95% CI,
21-39%) of patients achieved a full TCC in the peripheral blood.
At day 90, 77% (95% CI, 69-85%) had a full donor TCC. In
univariate analysis, none of the patient, graft, RIC type, or disease
characteristics could be predictive of establishment of an early full
donor TCC at day 30. However, the group of 31 patients who
achieved a full donor TCC by day 30, experienced a signiﬁcantly
higher incidence of grade 2-4 acute GVHD, in comparison to the
group of 71 patients who were still in mixed TCC at day 30
(cumulative incidence, 61% vs. 35%; P  .01). When looking for
predictive factors for full donor TCC at day 90, univariate analysis
showed that diagnosis category, the RIC type (ATG, TBI or
TLI-based RIC), a female donor, CD34 cell dose, and CD4 T
cell dose, were signiﬁcant or had a trend towards signiﬁcant asso-
ciation with establishment of full donor TCC by day 90. In mul-
tivariate analysis, a diagnosis other than a myeloid malignancy, was
the strongest parameter signiﬁcantly predictive of establishment of
full TCC at day 90 (P .007; OR 3.82; 95% CI, 1.4-10.1). Most
importantly, the delayed establishment of full donor TCC in pa-
tients with myeloid malignancies translated towards a worsened
PFS (P  .06) in the group of 15 patients who did not achieve full
donor TCC at day 90 as compared to the group of 26 patients who
achieved a full donor TCC. This worsened PFS was due to a
signiﬁcantly higher incidence of leukemia relapse among these 15
patients (6 relapses; 40%) as compared to none in the other group
of 26 patients (P  .002). Overall, we conclude that cautious
monitoring of the levels of donor TCC is mandatory after RIC
allo-SCT, because this can improve patient outcomes through
identiﬁcation of patients at risk for acute GVHD, and disease
progression, and guidance of early interventions with immunosup-
pressive drugs or DLI aimed at obviating these complications.
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PENTOSTATIN, TBI AND EXTRACORPOREAL PHOTOPHERESIS FOR RE-
DUCED-INTENSITY PREPARATION: SINGLE CENTER ADAPTATION OF
THE TUFTS EXPERIENCE
Abboud, C.N., Liesveld, J.L., Bernstein, S.H., Friedberg, J.,
Ifthikharuddin, J.J., Constine, L.S., Kaplan, K.L., Wedow, L.A.,
Nichols, D.D., Oliva, J., Etter, M., Phillips, G.L. James P Wilmot
Cancer Center, University of Rochester, Rochester, NY.
Conditioning regimens used in reduced intensity transplants are
designed to optimize immune suppression to allowing for prompt
engraftment and robust graft versus tumor effect. The Tufts reg-
imen (Miller KB, et al. Bone Marrow Transplant 2004;34:881) has a
reduced incidence of GVHD while demonstrating disease response
using extracorporeal photopheresis (ECP), pentostatin 4 mg/m2/
day 2 and a reduced dose of total body irradiation (TBI: 600 cGy
given in 3 fractions). We treated 45 patients with a minimum of 6
months follow up, median age of 55 years (27-67); 33 patients were
50 years or older; 25 received sibling and 20 an unrelated donor
(UD) transplant. All but one sibling transplant was a 6/6 match,
whereas 8/20 UD transplants involved mismatched loci. GVHD
prophylaxis consisted of tacrolimus and short course methotrexate
in 43, tacrolimus/MMF in 1 and tacrolimus/sirolimus in 1. Seven-
teen patients had AML, 3 MDS, 2 ALL, 2 CML, 11 CLL, 8 NHL,
1 HD and 1 lymphoplasmacytic lymphoma. Eight of the 45 had
prior stem cell transplantation. The median number of CD34
cells infused was 4.54 million/kg. Nine patients were transplanted
in CR or early disease phase. Five patients died before anticipated
neutrophil recovery, 2 had no neutrophil nadir and median time to
neutrophil engraftment was 14.5 days, and platelets recovered in
18.7 days. Donor chimerism at 30 days by VNTRs was 94% (range
34%-100%). The overall day 100 survival was 69% (31/45), with
80% (20/25) of sibling graft recipients alive and 55% (11/20) of
UD recipients still living. Twelve patients developed regimen
related toxicity. In ﬁve this manifested as ARDS or multiorgan
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